Counselors in Hollywood, MD Accepting Medicare

7 Counselors found. Showing 1 - 7

Glori Vanbrunt, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 23680 Three Notch Rd, Suite 202b, Hollywood, MD 20636 Phone: 240-223-2451    Fax: 240-223-2451

Mrs. Latoya Brandye Burnyce Adams-rodriguez, MA, LCPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 43469 Greg St, Hollywood, MD 20636 Phone: 240-309-1701

Ms. Judith A Semones, LCPC Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 44101 Airport View Drive, Hollywood, MD 20636 Phone: 301-373-3065    Fax: 301-373-6143

Kristen Lynn Walker, LGPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 44101 Airport View Dr, Hollywood, MD 20636 Phone: 301-373-3065

Mrs. Suzanne Janis Pelz, LCPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 44101 Airport View Drive, Hollywood, MD 20636 Phone: 301-373-3065    Fax: 301-373-6143

Mrs. Loriann Marie Bowes, MA Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 44101 Airport View Drive, Pathways, Hollywood, MD 20636 Phone: 301-373-3065    Fax: 301-373-6143

Amber Larie Abell, LGPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 44101 Airport View Dr, Hollywood, MD 20636 Phone: 301-373-3065    Fax: 240-309-4160

News Archive

Green nanotechnology from tea

Researchers from the University of Missouri-Columbia report in the Journal of Materials Chemistry that chemicals in tea are the best yet discovered to make consistent, biologically safe gold nanoparticles. More importantly, these gold nanoparticles show promising anticancer properties.

Prions may be crucial in brain development during childhood

A molecule that is not only dangerous, but can help the brain grow. A few years ago it was found that certain proteins, the prions, when defective are dangerous, as they are involved in neurodegenerative syndromes such as the Creutzfeldt-Jakob and the Alzheimer diseases.

AIM Health Group to raise $3.5 million through private placement

AIM Health Group Inc. ("AIM" or the "Company") (TSXV - AHG), a fully integrated health care company, announced today that it has engaged Raymond James Ltd., on a "commercially reasonable efforts" agency basis, to complete a private placement of up to $3.5 million principal amount of 10% convertible secured debentures (the "Debentures") to accredited investors.

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and arterial disease, today reported that it has initiated an open-label, multicenter Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E."

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

Read more Medical News

› Verified 8 days ago